These observations underscore three critical considerations for treatment: ensuring the complete clearance of anti-PLA2R antibodies to achieve full immunological remission, recommending a second course of RTX six months post-initial regimen, and emphasizing vigilant infection prevention strategies because of diminished immunity following RTX infusion. The gene discussed is PLA2R1; the disease is infection.